Regenerex Pharma, Inc. (RGPX) — SEC Filings
Regenerex Pharma, Inc. (RGPX) — 14 SEC filings. Latest: 8-K (May 6, 2026). Includes 6 8-K, 6 10-Q, 2 10-K.
View Regenerex Pharma, Inc. on SEC EDGAR
Overview
Regenerex Pharma, Inc. (RGPX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 17, 2025: REGENEREX PHARMA, INC. (RGPX) reported a significant increase in net loss for the six months ended September 30, 2025, reaching $1,477,596, a substantial rise from the $802,132 net loss in the prior year period. This was primarily driven by a surge in general and administrative expenses to $1,286,98
Sentiment Summary
Across 14 filings, the sentiment breakdown is: 3 bearish, 11 neutral. The dominant filing sentiment for Regenerex Pharma, Inc. is neutral.
Filing Type Overview
Regenerex Pharma, Inc. (RGPX) has filed 6 8-K, 6 10-Q, 2 10-K with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (14)
Risk Profile
Risk Assessment: Of RGPX's 13 recent filings, 3 were flagged as high-risk, 5 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$1,477,596 |
| EPS | -$0.00 |
| Debt-to-Equity | N/A |
| Cash Position | $11,659 |
| Operating Margin | N/A |
| Total Assets | $617,764 |
| Total Debt | $5,316,564 |
Key Executives
- CEO
- CFO
- Shareholder
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Regenerex Pharma are often pre-revenue for extended periods, relying on capital raises to fund operations. The competitive landscape includes established players with substantial resources and emerging biotechs, making market entry and commercialization challenging.
Top Tags
10-Q (4) · pharmaceuticals (4) · quarterly-report (3) · Biotechnology (2) · Going Concern (2) · High Risk (2) · corporate-governance (2) · material-agreement (2) · Penny Stock (1) · Liquidity Crisis (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1,477,596 | Increased from $802,132 year-over-year for the six months ended September 30, 2025. |
| Cash and Equivalents | $11,659 | Dramatic decrease from $653,025 at March 31, 2025, indicating severe liquidity issues. |
| Accumulated Deficit | $9,620,486 | Increased from $8,142,891 at March 31, 2025, highlighting ongoing operational losses. |
| Total Stockholders' Deficit | $4,698,800 | Worsened from $4,156,205 at March 31, 2025, reflecting negative equity. |
| General and Administrative Expenses | $1,286,987 | More than doubled from $512,664 in the prior year period, contributing to increased losses. |
| Revenue | 0 | No revenue generated from acquired assets, despite significant operating expenses. |
| Common Shares Outstanding | 282,372,310 | As of November 17, 2025, indicating a large share count for a pre-revenue company. |
| Outstanding Warrants and Options | 10,625,352 | As of September 30, 2025, representing potential future dilution. |
| Excess Liabilities over Assets | $4,547,656 | As of June 30, 2025, contributing to going concern doubt |
| Incremental Borrowing Rate | 10% | Used for lease liabilities discount |
| Net Loss (FY2025) | $1,000 | Significantly reduced from $10,000 in FY2024, but still a loss. |
| Net Loss (FY2024) | $10,000 | Prior year's net loss, showing a 90% improvement in loss reduction. |
| CEO/CFO Advances (FY2025) | $1,000 | Total advances from CEO and CFO, down from $10,000 in FY2024, indicating continued reliance on related-party funding. |
| Promissory Note from Shareholder | $10,000 | Outstanding related-party debt as of March 31, 2025, highlighting external financial dependence. |
| Intellectual Property Purchase | $100,000 | Significant asset acquired on November 15, 2021, representing core business focus. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Regenerex Pharma, Inc. (RGPX)?
Regenerex Pharma, Inc. has 14 recent SEC filings from Feb 2024 to May 2026, including 6 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RGPX filings?
Across 14 filings, the sentiment breakdown is: 3 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find Regenerex Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Regenerex Pharma, Inc. (RGPX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Regenerex Pharma, Inc.?
Key financial highlights from Regenerex Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RGPX?
The investment thesis for RGPX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Regenerex Pharma, Inc.?
Key executives identified across Regenerex Pharma, Inc.'s filings include CEO, CFO, Shareholder.
What are the main risk factors for Regenerex Pharma, Inc. stock?
Of RGPX's 13 assessed filings, 3 were flagged high-risk, 5 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Regenerex Pharma, Inc.?
Forward guidance and predictions for Regenerex Pharma, Inc. are extracted from SEC filings as they are enriched.